H
Herbert Haack
Researcher at Cell Signaling Technology
Publications - 33
Citations - 4181
Herbert Haack is an academic researcher from Cell Signaling Technology. The author has contributed to research in topics: Cancer & Anaplastic lymphoma kinase. The author has an hindex of 14, co-authored 33 publications receiving 3870 citations. Previous affiliations of Herbert Haack include Massachusetts Institute of Technology.
Papers
More filters
Journal ArticleDOI
Global Survey of Phosphotyrosine Signaling Identifies Oncogenic Kinases in Lung Cancer
Klarisa Rikova,Ailan Guo,Qingfu Zeng,Anthony Possemato,Jian Yu,Herbert Haack,Julie Nardone,Kimberly Lee,Cynthia Reeves,Yu Li,Yerong Hu,Zhi-Ping Tan,Matthew P. Stokes,Laura Sullivan,Jeffrey Mitchell,Randy Wetzel,Joan MacNeill,Jian Min Ren,Jin Yuan,Corey E. Bakalarski,Judit Villén,Jon M. Kornhauser,Bradley L. Smith,Daiqiang Li,Xinmin Zhou,Steven P. Gygi,Ting-Lei Gu,Roberto D. Polakiewicz,John Rush,Michael J. Comb +29 more
TL;DR: By focusing on activated cell circuitry, the approach outlined here provides insight into cancer biology not available at the chromosomal and transcriptional levels and can be applied broadly across all human cancers.
Journal ArticleDOI
Diagnosis of NUT midline carcinoma using a NUT-specific monoclonal antibody.
Herbert Haack,Laura A. Johnson,Christopher J. Fry,Katherine Crosby,Roberto D. Polakiewicz,Edward B. Stelow,Seung-Mo Hong,Brian E. Schwartz,Michael J. Cameron,Mark A. Rubin,Martin C. Chang,Jon C. Aster,Christopher A. French +12 more
TL;DR: IHC staining with the C52 monoclonal antibody is a highly sensitive and specific test that reliably distinguishes NMC from other forms of carcinoma.
Journal ArticleDOI
PD-L1 Expression Correlates with Tumor-Infiltrating Lymphocytes and Response to Neoadjuvant Chemotherapy in Breast Cancer
Hallie Wimberly,Jason R. Brown,Kurt A. Schalper,Herbert Haack,Matthew Ren Silver,Christian Nixon,Veerle Bossuyt,Lajos Pusztai,Donald R. Lannin,David L. Rimm +9 more
TL;DR: PD-L1 expression was observed in 30% of patients, and it was positively associated with hormone-receptor–negative and triple-negative status and high levels of TILs, indicating a subset of patients that may benefit from immune therapy.
Journal ArticleDOI
Survey of Tyrosine Kinase Signaling Reveals ROS Kinase Fusions in Human Cholangiocarcinoma
Ting-Lei Gu,Xiaxing Deng,Feizhou Huang,Meghan Ann Tucker,Katherine Crosby,Victoria Rimkunas,Yi Wang,Gang Deng,Lei Zhu,Zhi-Ping Tan,Yerong Hu,Chun-Lin Wu,Julie Nardone,Joan MacNeill,Jianmin Ren,Cynthia Reeves,Gregory Innocenti,Brett Norris,Jin Yuan,Jian Yu,Herbert Haack,Baiyong Shen,Chenghong Peng,Hongwei Li,Xinmin Zhou,Xunyang Liu,John Rush,Michael J. Comb +27 more
TL;DR: It is demonstrated that ROS kinase is a promising candidate for a therapeutic target and for a diagnostic molecular marker in cholangiocarcinoma and suggests that a more broadly based screen for activated ROS kinases in cancer is warranted.
Journal ArticleDOI
Analysis of Receptor Tyrosine Kinase ROS1-Positive Tumors in Non–Small Cell Lung Cancer: Identification of a FIG-ROS1 Fusion
Victoria Rimkunas,Katherine Crosby,Daiqiang Li,Yerong Hu,Meghan E. Kelly,Ting-Lei Gu,Jennifer S. Mack,Matthew Ren Silver,Xinmin Zhou,Herbert Haack +9 more
TL;DR: The ROS1 IHC assay described here is a valuable tool for identifying patients expressing mutant ROS1 and could be routinely applied in clinical practice to detect lung cancers that may be responsive to targeted therapies.